Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.

  title={Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.},
  author={Amishi Vijay Vora and Manisha Bhutani and A. K. Sharma and Vinod Raina},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  volume={13 11},
  • A. Vora, M. Bhutani, V. Raina
  • Published 1 November 2002
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
Signal transduction inhibitor 571 (STI 571), a potent and selective inhibitor of the tyrosine kinase activity of BCR– ABL, is an important advance in the treatment of chronic myelogenous leukemia (CML) patients in the advanced phase of disease or those with chronic phase (CP) intolerant or resistant to interferon (IFN) therapy [1–3]. Given at the dose of 400–600 mg p.o. daily, STI 571 is generally well tolerated. Common adverse effects include mild to moderate myelosuppression, nausea, vomiting… 
Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase
AMN107 (Nilotinib) has been developed from imatinib, as a more potent inhibitor of Bcr-Abl, which has substantially increased binding affinity and selectivity for the Abl kinase compared with imatin ib, and shows 20to 50fold greater potency.
Tumor Lysis Syndrome in the Chronic Phase of Chronic Myeloid Leukemia Following COVID-19 Infection: A Case Report
Although CML rarely presents with TLS, physicians should monitor their patients closely, especially those who have concurrent COVID-19 infection, as this condition may result in lethal sequelae such as AKI, severe arrhythmias, and multiorgan failure.
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis.
Tumor Lysis Syndrome in Lymphoblastic Crisis of CML
A 45-yr-old woman presenting with TLS associated with CML in lymphoblastic crisis after the initiation of cytotoxic chemotherapy is reported, with a high incidence of TLS in tumors with high proliferative rates and large burden.
Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Experience in the current case suggests that preventive measures for tumor lysis syndrome should be taken for patients with high leukemia burden who receive imatinib therapy, and parameters of tumors lysis should be monitored in the early phase of therapy.
Chronic myelogenous leukaemia (CML): an update.
  • L. Kumar
  • Medicine
    The National medical journal of India
  • 2006
Most investigators agree that patients who fail to achieve CHR by 12 weeks, have partial cytogenetic response (< 35% Ph-positive metaphases) at 12 months, have CGR by 18 months, who relapse after initial response to imatinib, and those with a high Sokal score or in an advanced phase of CML should be considered for allogeneic stem cell transplantation (SCT).
Acute Tubular Injury Associated with Imatinib (Gleevec): A Case Report and Review of the Literature
A 76-year-old woman with a GIST tumor treated with imatinib mesylate is presented and there is no radiographic evidence of disease and her renal function remained stable at 1.6 mg/dL.
Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia
Tumor lysis syndrome happening after starting Imatinib myselate is reported in chronic myelogenous leukemia, one of the myeloproliferative disorders.
Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report
The first case of a patient with imatinib‐resistant CML who developed PE and acute renal failure (ARF) simultaneously, after being placed on dasatinib therapy is reported.
Hypersensitivity and Tumor Lysis Syndrome Associated with Cetuximab Treatment: Should We be Afraid?
In the patient with widespread bone and liver metastases, treatment continued with cetuximab as a combination therapy with irinotecan in spite of the hypersensitivity and TLS led to a complete treatment response.


Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase, and a daily dose of 600 mg is more effective than 400 mg, with similar toxicity.
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
The BCR-ABL tyrosine kinase inhibitor STI571 is well tolerated and has substantial activity in the blast crises of CML and in Ph-positive ALL.
STI571: a paradigm of new agents for cancer therapeutics.
The identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality are reviewed.
Tumor lysis syndrome after STI 571 in Philadelphia chromosome positive acute lymphoblastic leukemia
  • J Clin Oncol
  • 2002
DOI: 10.1093/annonc
  • DOI: 10.1093/annonc